2016 American Transplant Congress » Poster Session C: Viruses and SOT
Date: Monday, June 13, 2016
Time: 6:00pm-7:00pm
Location: Halls C&D
Session Type: Poster Session
Meeting: 2016 American Transplant Congress
- 6:00pm-7:00pm
Adenovirus Infection in Kidney Transplant Recipients: Report of a Case Series.
C. Simancas-Ruiz, L. Marino-Vazquez, A. Meraz-Muñoz, A. Nuñez-Abreu, R. Rivera-Marfil, N. Uribe-Uribe, J. Alberu, L. Morales-Buenrostro.
- 6:00pm-7:00pm
An Evaluation of the Safety, Efficacy, and Pharmacoeconomics of Two Valganciclovir Prophylaxis Regimens Following Renal Transplantation.
J. Chen,1 R. Hoffman,2 M. Thomas,2 J. Gervasio.2
- 6:00pm-7:00pm
CMV Monitoring Reduces Risk of Clinical Complications in Kidney Transplant Recipients.
A. Gilbert, M. Cooper, J. Verbesey, R. Ghasemian, P. Abrams, J. Moore, M. Grafals, J. Chahine, S. Punnett, E. Hall, I. Anzak, B. Javaid.
- 6:00pm-7:00pm
Characteristics of Human Rhinovirus (HRV) Infections in Transplant Recipients.
H. Crossman,1 M. Barron,1 M. Levi.1
- 6:00pm-7:00pm
Clinical Predictors of Progression and Clearance of Low Level CMV Viremia in Solid Organ Transplant Recipients.
A. Alghamdi, A. Humar, Y. Natori, S. Husain, L. Singer, E. Renner, C. Rotstein, D. Kumar.
- 6:00pm-7:00pm
Comparative Effectiveness of Cytomegalovirus Prevention Strategies in a Large Retrospective Cohort of Kidney Transplant Recipients.
C. Santos, M. Saeed, D. Brennan, M. Olsen.
- 6:00pm-7:00pm
Cytomegalovirus Infection After Cardiac Transplantation.
O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
- 6:00pm-7:00pm
Development of a Sequencing-Based Cytomegalovirus UL55 Glycoprotein B (gB) Genotyping Assay.
S. Cowden, K. Grantham, I. Caton, J. Hester, M. Altrich, S. Kleiboeker.
- 6:00pm-7:00pm
Direct Detection of T and B Memory Lymphocytes Reveals HCMV Exposure That Serum Antibodies Fail to Identify.
S. Sundararaman, F. Terlutter, T. Nowacki, R. Caspell, P. Lehmann.
- 6:00pm-7:00pm
Donor Transmited Rabies Outbreak Involving Four Transplant Recepients in Kuwait and Saudi Arabia.
H. Elsiesy,1,2 I. Hussain,3 F. Abaalkhail,1,2 W. Al-Hamoudi,1 H. Elbeshbeshy,1 M. Al Sebayel,1 D. Broering,1 A. Elgohary,1 S. Al Fawaz,4 S. Althawadi,5 J. Alotaibi,4 H. AlHindi,5 P. Nair,6 T. Al- Otaibi,6 N. Nampoory,6 L. Orciar,7 A. Velasco-Villa,7 P. Yager,7 T. Smith,7 W. Carson,7 M. Niezgoda,7 A. Wadhwa,7 R. Edgar Condori,7 Y. Li,7 R. Franka,7 M. Halim,4 R. Willoughby.8
- 6:00pm-7:00pm
Down-Regulated of Circulating miR-29b, miR-185 and NR_073415.2 in Post-Transplanted Patients with Cytomegalovirus Infection May Serve as Novel Biomarkers for Early Diagnosis.
A. Yang, W. Ju, Z. Guo, C. Wu, J. Lin, M. Chen, R. Deng, E. Chen, Y. Gao, X. Zhu, X. He.
- 6:00pm-7:00pm
Evaluating Posttransplant BKV-Specific T Cell Responses in Patients with Alemtuzumab Induction and Belatacept-Based Regimen.
M. McRae, T. How, A. Kirk, H. Xu.
- 6:00pm-7:00pm
Evaluation of the Impact of the Implementation of a Specialty Pharmacy Program in the Treatment of Hepatitis C (HCV).
E. Aldag, T. Pedone, R. Pedersen, S. Besur, K. Safdar, A. Sahajpal.
- 6:00pm-7:00pm
Hepatitis B Reactivation Among Non-Liver Solid Organ Transplant Recipients.
A. Gonzalez, F. Forouton, A. Humar, S. Husain.
- 6:00pm-7:00pm
Implementation of a Risk Stratified Approach for Prevention of Hepatitis B Reactivation Post Kidney Transplant.
M. Cote,1 M. Pavlakis,2 J. Ethridge,1 C. Currier,2 M. Curry,2 E. Khankin,2 F. Cardarelli,2 K. Richards,1,2 C. Rogers.1,2
- 6:00pm-7:00pm
Influence of Country-Associated Geographical Variables in the Ouctomes of Kidney Transplantation in Patients with HIV-Infection.
M. Cristelli,1 F. Cofán,2 H. Tedesco-Silva,1 J. Trullas,3 D. Santos,1 C. Manzardo,4 F. Aguero,4 A. Moreno,4 F. Oppenheimer,2 F. Dieckmann,1 J. Miro,4 J. Medina-Pestana.1
- 6:00pm-7:00pm
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
C. Burton, Y. Tong, J. Preiksaitis.
- 6:00pm-7:00pm
Kinetics of Cytomegalovirus Load in Kidney Transplant Recipients Receiving Everolimus or Mycophenolate Sodium and No Pharmacological Prophylaxis.
G. Basso, C. Felipe, A. Ferreira, M. Cristelli, N. Oliveira, T. Sandes-Freitas, J. Mansur, L. Viana, W. Aguiar, E. Campos, M. Gerbasi-DeLima, H. Tedesco-Silva, J. Medina-Pestana.
- 6:00pm-7:00pm
Neuro-invasive Saint Louis Encephalitis Virus (SLEV) Infection in Solid Organ Transplant Recipients in a Non-Endemic Area.
C. Hartmann, I. Qaqish, T. Grys, H. Vikram, M. Seville, R. Orenstein, S. Kusne, J. Blair, R. Patron.
- 6:00pm-7:00pm
Outcomes of Solid Organ Transplantation from an HIV Positive Donor to Negative Recipients.
S.-N. Lin,1 M.-K. Tsai,1 C.-Y. Luo,2 C.-Y. Lee,1 R.-H. Hu,1 J.-M. Lee,1 H.-S. Lai.1
- 6:00pm-7:00pm
Outcomes of Transplant Recipients Treated with Cidofovir for Resistant or Refractory Cytomegalovirus Infection.
S. Mehta, M. Alfares, A. Valsamakis, S. Shoham, R. Boger, L. Lees, D. Ostrander, R. Avery.
- 6:00pm-7:00pm
Parainfluenza-3 Infections Early After Kidney Transplantation.
I. Helanterä,1 V.-J. Anttila,2 M. Lempinen.1
- 6:00pm-7:00pm
Parameters of Uremia-Associated Premature Ageing of Peripheral T Cells Do Not Predict Infectious Complications After Renal Transplantation.
B. Dedeoglu, R. Meijers, M. Klepper, D. Hesselink, C. Baan, N. Litjens, M. Betjes.
- 6:00pm-7:00pm
Polyfunctionality of CD8 T Cell Responses to Cytomegalovirus in Transplant Patients.
L. Higdon,1 K. Margulies,2 J. Maltzman.1,3
- 6:00pm-7:00pm
Predictors of Post Transplant Lymphoprolipherative Disorder Among Adult Kidney Transplant Recipients.
M. Mohamed, S. Parajuli, B. Muth, A. Djamali, B. Astor.
- 6:00pm-7:00pm
Preemptive CMV Prophylaxis in Renal Transplant Recipients Receiving Everolimus Immunosuppression Reduces Cytomegalovirus Infection.
G. Spagnoletti, M. Salerno, V. Bianchi, N. Silvestrini, F. Apponi, J. Romagnoli.
- 6:00pm-7:00pm
Prophylactic Anti-Virus Therapy, Is It Necessary to Occult Hepatitis B Virus Carriers with HBsAg(-) and HBcAb(+) After Kidney Transplantation?
G. Chen, C. Wang, L. Chen, J. Qiu, C. Wang.
- 6:00pm-7:00pm
Quantiferon-CMV Test, CMV-Specific ELISPOT and CMV-Dextramer Assays in Assessing the Risk of CMV Infection in Seropositive Kidney Transplant Recipients.
H. Lee,1 K. Park,2 J. Ryu,2 J. Yu,3 B. Chung,3 C. Yang,3 E.-J. Oh.1
- 6:00pm-7:00pm
Reduced-Dose Cidofovir (CID) and CMV-Hyperimmune Globulin (CMVIg) for Ganciclovir-Resistant Cytomegalovirus: Effective and Kidney Friendly.
S. Patel, S. Kuten, J. Snyder, R. Knight, A. Gaber.
- 6:00pm-7:00pm
Risk Factors for the Development of CMV Viremia in a Cohort of Morbidly Obese Kidney Transplant Recipients Under Low Dose Valganciclovir Prophylaxis.
J. Thielke,1 N. Jasiak,1 N. Hilal,1 S. Salah,1 E. Benedetti,2 P. West-Thielke.2
« View all sessions from the 2016 American Transplant Congress